Skye Bioscience, Inc. Nasdaq Warning Explained

1. What happened? (in plain English - the actual event)

Here's the big news: Skye Bioscience received a warning from Nasdaq. Nasdaq is the major stock exchange where its shares trade. The warning, under Nasdaq Listing Rule 5550(a)(2), states the company's stock price has been too low. Its common stock, traded on the Nasdaq Global Market, failed to stay above $1.00 per share. If they don't fix this, Nasdaq could remove their shares. This process is called delisting.

2. When did it happen?

Skye Bioscience received this notice on March 17, 2026. The company then publicly announced it in a filing on March 19, 2026.

3. Why did it happen? (context and background)

Here's some background. The reason for the warning is simple: Nasdaq Rule 5550(a)(2) requires companies to keep their stock price above $1.00. Skye's stock (SKYE) traded below $1.00 for 30 business days. This triggered the warning. A low stock price often shows investor worries. It can reflect doubts about the company's future, its money, or lack of good news.

Skye Bioscience is a biotech company. It develops new medicines, especially using cannabinoids. These treat serious conditions like glaucoma and metabolic disorders. Biotech stocks like Skye often have volatile prices. Their success depends on risky, expensive drug development. This includes preclinical and clinical trials. Good news, like successful trials, can boost shares. Bad news, like trial failures, can make them drop. Delays or lack of progress also hurt prices. The low stock price suggests investors lack recent positive news. They may worry about drug development. Concerns also include available cash or early-stage biotech sentiment.

4. Why does this matter? (impact and significance)

Why does this matter? This is bad news for Skye Bioscience. Here's why:

• Risk of Delisting: Skye's stock could be removed from Nasdaq. This is the most immediate concern. A Nasdaq listing offers credibility and visibility. It also makes shares easier to buy and sell. It gives access to many investors, both big and small. This usually means shares are easier to trade. If delisted, the stock might move to an "over-the-counter" (OTC) market. Examples include OTCQB or Pink Sheets. OTC markets are less regulated. They have lower trading volume and wider price gaps. Investors find these shares much harder to trade. Many big investors cannot hold stocks not on a major exchange. This often causes a big drop in share price. It also makes it much harder for the company to raise money.
• Investor Confidence: A delisting notice signals struggles. It shows the company cannot meet basic exchange rules or maintain value. This hurts investor confidence. Skye may struggle to attract or keep investors. Current shareholders might sell their stock.
• Company Reputation: This hurts the company's reputation. It impacts scientific, investment, and pharma groups. It can make attracting talent harder. Securing drug partnerships or future funding also becomes tougher.

5. Who is affected? (employees, customers, investors, etc.)

Who feels this the most?

• Investors (that's you!): You are likely the most affected group. The stock price may stay low or drop more. This is due to Nasdaq listing uncertainty. If delisted, selling shares becomes harder. Their value could drop significantly. Less trading and big investors selling cause this. Some brokers may even limit trading of OTC stocks.
• The Company (Skye Bioscience): Its ability to raise money is at risk. Its reputation and standing in biotech also face risk. Losing a Nasdaq listing is a serious blow. It can hurt operations and long-term plans.
• Employees: Their jobs could be impacted. This happens if the company struggles to recover. Or if it cannot raise money for research. Uncertainty can also hurt employee morale and retention.
• Potential Patients: This event does not directly impact drug development now. But if the company's money situation worsens, funding trials could suffer. This might delay or halt new treatments. This affects conditions like glaucoma or metabolic disorders.

6. What happens next? (immediate and future implications)

What happens next? Skye Bioscience has a tight deadline to fix this.

• 180-Day Window: They have 180 days, until September 14, 2026. They must get their stock price back up. Nasdaq Rule 5810(c)(3)(A)(ii) grants this period.
• How to Regain Compliance: To fix it, their stock must close at $1.00 or more. This must happen for 10 business days. It must occur within the 180-day period.
• Options: The company will "actively monitor" the stock price. They will "consider available options." A common option is a reverse stock split. This reduces total shares and increases price per share. For example, 10 shares at $0.50 become 1 share at $5.00. It boosts the price to meet Nasdaq rules. But it does not change your investment's total value. It also doesn't change the company's market value. Investors often view it negatively. It can signal underlying business struggles. If chosen, they need to complete it by September 4, 2026. This allows time for the 10-day compliance period.
• Second Chance (Maybe): If they miss the September 14 deadline, they might get a second 180-day period. To qualify for a second chance, they must meet other Nasdaq rules. These include a $5 million market value for public shares. They also need $2.5 million in owner's equity. They must also tell Nasdaq their plan. This is under Nasdaq Listing Rule 5810(c)(3)(A)(ii). If granted, this second period would last until March 13, 2027.
• No Guarantees: The company stated "no assurance" they will regain compliance. This is true even with a reverse split or other strategies.

7. What should investors/traders know? (practical takeaways)

Here's what investors should know:

• Increased Volatility: Expect more ups and downs. Nasdaq listing uncertainty will keep the stock price jumpy. This will happen as the deadline nears. News on trials or funding could also cause big swings.
• Delisting Risk is Real: Understand that Skye could be delisted. This happens if its stock price stays low. This is a big event. It can severely impact your investment's value. Selling shares at a fair price might become difficult.
• Reverse Stock Split Ahead? Watch for any reverse stock split announcements. It can temporarily solve the price issue. But it doesn't change the company's underlying value. It also doesn't change its cash use or business prospects. Investors should evaluate the company's basics. Do this regardless of the share price.
• Focus on the Core Business: The listing issue is critical. But understand why the stock price fell. Is it due to slow drug development? This includes trial delays or bad results. Or challenges in getting research funding? Are there bigger money worries? Like little available cash or big operating losses? The listing issue is a symptom. It's not necessarily the root cause of valuation problems.
• High Stakes: This adds more risk to an already risky biotech investment. Weigh recovery potential against delisting risk. Recovery could come from good trial data or new funding. Delisting means further value loss. Monitor their upcoming trial milestones and financial reports. These offer insights into their health.